ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 7 of 19 for:    "Burning Mouth Syndrome"

Opiorphin Levels in Fluids of Burning Mouth Syndrome Patients (OPIODYN) (OPIODYN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02686359
Recruitment Status : Completed
First Posted : February 19, 2016
Last Update Posted : February 19, 2016
Sponsor:
Collaborator:
Institut Pasteur
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Brief Summary:
If epidemiological studies indicate relatively low prevalence reported in the general population, idiopathic burning mouth syndrome (BMS) is a common condition among certain groups of the population: 30% of menopausal women experience oral burning to varying degrees . Despite significant progress made in recent years, in understanding the physiopathogeny, treatment options remain limited and disappointing,resulting in an impairment of the quality of life. Given the chronic nature of idiopathic burning mouth syndrome, the need to identify the causes and effective treatment modalities for subjects suffering is essential.

Condition or disease Intervention/treatment Phase
Burning Mouth Syndrome Biological: sample Not Applicable

Detailed Description:

Idiopathic burning mouth syndrome (BMS) is a chronic orofacial pain condition in which the pain is felt as intense, located on the tongue and the oral mucosa with no known cause. The pain may last for years and present treatments are of little effect. BMS is primarily a feminine disease, affecting women during or following menopause, suggesting an etiopathogenic role of the sexual hormones potentiating a local salivary factor. An anxiodepressive component is often associated with the disease. Recently, a molecule named opiorphin has been identified in human saliva. In animals, this molecule has shown potent analgesic properties comparable to those of morphine. The hypothesis of the investigators is that this molecule is in lower quantity in the saliva of persons suffering BMS and that this decrease causes oral burning sensations.

The main objective of the study is to test the hypothesis of a decrease of opiorphin levels in the saliva of patients suffering from primary BMS compared to a group of control subjects. The main judgment criteria is the level of salivary opiorphin in ng/mL.

The proposed study is a multicentric, simple blinded case controlled study. The investigators will collect the data from 21 primary BMS patients and 21 control subjects matched in sex, age, and hormonal status (menopause). The alpha risk is 0.5% and the power of the study is 90%.

Criteria for inclusion : BMS patients will be suffering for more than 4 months from burning pain in the tongue or oral mucosa with no organic trouble detectable by anamnesis, clinical evaluation and biological testing.

The design of the study includes three sessions for all subject of both groups; the maximum duration of participation for a subject is 8 weeks and the total duration of the study is 24 months There are two investigation centers.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 42 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single (Care Provider)
Primary Purpose: Diagnostic
Official Title: Research of a Biological Marker for Chronic Orofacial Pain: Dosage of Opiorphin in Patients With Burning Mouth Syndrome
Study Start Date : July 2011
Actual Primary Completion Date : December 2012
Actual Study Completion Date : December 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Burns

Arm Intervention/treatment
Experimental: Burning Mouth Syndrome Patients
saliva, blood and urinary samples
Biological: sample
Active Comparator: controls
saliva, blood and urinary samples
Biological: sample



Primary Outcome Measures :
  1. opiorphin levels in saliva [ Time Frame: Day 30 ]

Secondary Outcome Measures :
  1. opiorphin levels in blood [ Time Frame: Day 30 ]
  2. urinary levels in urine [ Time Frame: Day 30 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Clinical diagnosis of Burning Mouth Syndrome
  • Age between 18 and 80 years
  • Sensation of pain in the oral mucosa, meeting the diagnostic criteria for BMS (Bergdahl and Anneroth, 1993, Scala 2003)
  • Signature of informed consent

Healthy volunteers

  • Age between 18 and 80 years
  • Patient age (+/- 5 years), sex and hormonal status (menopause or not for women) matched with a Burning Mouth Syndrome patient
  • Signature of informed consent

Exclusion Criteria:

  • Dental or periodontal pain during the month before the visit
  • General pathology likely to cause mouth pain (diabetes, lupus, shingles, gastric reflux, allergies ...)
  • Chronic Orofacial pain other than Burning Mouth Syndrome
  • Treatment with a molecule able to induce oral burning sensations (anti-VEGF, neuroleptics, IEC angiotensin II ...)
  • Participation concomitantly in biomedical research
  • No affiliation to a social protection system
  • Taste disorder other than a dysgeusia linked to Burning Mouth Syndrome
  • Inability to understand the information note and sign the informed consent

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT02686359     History of Changes
Other Study ID Numbers: P081106
First Posted: February 19, 2016    Key Record Dates
Last Update Posted: February 19, 2016
Last Verified: February 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Assistance Publique - Hôpitaux de Paris:
physiology
pain
analgesia
saliva
opiorphin

Additional relevant MeSH terms:
Syndrome
Burns
Burning Mouth Syndrome
Disease
Pathologic Processes
Wounds and Injuries
Mouth Diseases
Stomatognathic Diseases